SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

20+ SynCardia Certified Centers to Present Record Number of Total Artificial Heart Abstracts at ISHLT

Topics Include Home Discharge Using the Freedom® Portable Driver and Use of the Total Artificial Heart for Adolescents, Congenital Patients and Destination Therapy


The 50cc SynCardia Total Artificial Heart is designed for use in patients of smaller stature, including women and adolescents. It has been designated as a Humanitarian Use Device (HUD) by the FDA for destination therapy and pediatric bridge to transplant. Prior to clinical use, a Humanitarian Device Exemption (HDE) application for each indication must be approved by the FDA.

TUCSON, Ariz. – April 11, 2013 – SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that more than 20 SynCardia Certified Centers representing four countries and more than 70 authors will present a record number of abstracts discussing the SynCardia temporary Total Artificial Heart at the annual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-27 in Montreal, Canada.

“Transplant programs throughout the world are making the SynCardia Total Artificial Heart the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia Chairman/CEO/President. “SynCardia Certified Centers have amassed a wealth of knowledge and experience in using the Total Artificial Heart, and sharing this information with the international transplant community is critical to creating and sustaining good patient outcomes worldwide.” 

Key ISHLT presentations on the SynCardia Total Artificial Heart, ordered by date and time, include:

Wednesday, April 24, 2013

  • 3:25 PM: Total Artificial HeartTotal Artificial Heart
    Francisco A. Arabia, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
    SYMPOSIUM 13: Machines vs. Medications for Biventricular Failure (2:15 PM-4:15 PM)
    Room: 517CD

Thursday, April 25, 2013

Friday, April 26, 2013

Saturday, April 27, 2013

In addition, on Wednesday, April 24, SynCardia will be hosting a panel discussion titled, “Moving Forward: The Freedom Experience, the Bi-Leaflet Valve TAH, and End-Organ Recovery.” Medical professionals interested in attending should contact Vivian Wessel at


About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright,, (520) 547-7463


Search offcanvas